Arcutis Biotherapeutics, Inc.

Q2 2026 net product revenues were $129.9 million, up 59% from Q2 2025 and up 23% from Q1 2026. Cost of sales was $10.9 million versus $7.5 million a year ago; R&D was $20.4 million versus $19.5 million; SG&A was $82.1 million versus $69.2 million. Net income was $15 million versus a net loss of $15.9 million in Q2 2025. Cash and marketable securities ended the quarter at $238.9 million, with positive operating cash flow of $12.6 million and total debt of $101.9 million. Management raised full-year 2026 net revenue guidance to $525 million-$540 million from $480 million-$495 million and expects continued quarter-over-quarter sales growth, with gross-to-net remaining in the 50s and trending to the low 50s by year-end.

Frank Watanabe framed the quarter as another step in Arcutis’ three-pillar strategy: grow the core ZORYVE business, expand into new indications, and build the pipeline beyond ZORYVE. He emphasized that the company is reinvesting cash flow from ZORYVE into commercial expansion, patient access tools, and pipeline work, calling the business a “virtuous cycle” of innovation. His tone was upbeat and confident, especially around the FDA wins in pediatric psoriasis and the accepted infant AD filing.

Latha Vairavan highlighted the quarter’s financial leverage: $129.9 million of net product revenue, stable gross-to-net in the 50s, and profitability with $15 million in net income. She noted that SG&A rose to $82.1 million mainly due to personnel costs tied to the dermatology sales expansion, while R&D was relatively flat at $20.4 million because higher medical affairs and ARQ-224 spending offset lower infant AD trial costs. She also said Arcutis ended the quarter with $238.9 million in cash and marketable securities, generated $12.6 million of operating cash flow, expects positive cash flow for the rest of the year, and plans to keep investing capital back into growth.

Analysts pressed on what is driving the higher second-half outlook, and management said growth should come primarily from prescription demand, with only modest gross-to-net improvement. On telehealth, Frank said the platform is meant to reach patients who cannot easily access dermatologists and that most prescriptions should still run through insurance, with the process designed to mirror office-based access rather than cash-pay models. Questions also focused on vitiligo, gross-to-net, the PCP/pediatric sales build, and the CEO transition; management said vitiligo enrolled well, the PCP/peds team is focused on a small but high-value slice of a large market, and Todd Edwards’ departure should be seamless because the commercial team is already strong and Rob Lisicki will overlap before taking over as interim CCO.